Tech Company Financing Transactions
Outrun Therapeutics Funding Round
On 4/18/2024, Outrun Therapeutics received $10 million in Seed financing from M Ventures and MP Healthcare Venture Management.
Transaction Overview
Company Name
Announced On
4/18/2024
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Errol Road Invergowrie
Dundee Scotland, DD2 5DA
UK
Dundee Scotland, DD2 5DA
UK
Phone
Undisclosed
Website
Email Address
Overview
Outrun Therapeutics is a preclinical biotech using E3 ligase inhibition to unlock the therapeutic potential of protein stabilisation for the treatment of cancer and other diseases. Spun out of founder Prof. Satpal Virdee's lab at the world-renowned MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, we are led by a seasoned management team, backed by M Ventures and MP Healthcare Venture Management.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Anthony Johnson
Chief Executive Officer
Carolyn Porter
Browse more venture capital transactions:
Prev: 4/18/2024: Pathios Therapeutics venture capital transaction
Next: 4/18/2024: Verne venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs